The Globe and Mail reports in its Wednesday edition that Pfizer and U.S. President Donald Trump have cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief. A Reuters dispatch to The Globe quotes Mr. Trump saying that Pfizer would offer that most-favoured-nation pricing on all new drugs launched in the U.S. and flagged that other drugmakers will follow suit. Shares of Pfizer rose more than 6 per cent, and the news lifted Eli Lilly, Merck, Amgen, AbbVie and GSK shares as well on investor relief that they would escape the worst of tariffs. U.S. patients currently pay by far the most for prescription medicines, and Mr. Trump has been pressuring drugmakers to lower their prices to those in other countries. Pfizer will be part of the White House's new direct-to-consumer website for Americans to buy drugs, called TrumpRx, that will launch in 2026. Several drugmakers have already set up direct-to-consumer pricing for some of their drugs, to be listed on a new website from the U.S. lobby group PhRMA, and raised the prices of their therapies in Britain in line with Mr. Trump's demands.